This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Christina Marie Kiley: Innovator in Dopaminergic CNS Disorders
Introduction
Christina Marie Kiley is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of pharmacology, particularly in the treatment of dopaminergic central nervous system (CNS) disorders. Her innovative work has the potential to impact the lives of many individuals suffering from various neurological conditions.
Latest Patents
Christina holds a patent for her invention titled "Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders." This patent encompasses dosing regimens and methods for utilizing LY3154207, a compound designed to treat a range of dopaminergic CNS disorders. These disorders include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia, Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders. Christina's patent represents a significant advancement in the treatment options available for these complex conditions.
Career Highlights
Christina is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its commitment to innovation and improving patient outcomes. Her work at Eli Lilly has allowed her to collaborate with some of the brightest minds in the industry, further enhancing her expertise and contributions to the field.
Collaborations
One of Christina's notable collaborators is Kevin Michael Biglan. Their partnership exemplifies the collaborative spirit that drives innovation in the pharmaceutical industry.
Conclusion
Christina Marie Kiley's work in developing dosing regimens for LY3154207 highlights her dedication to addressing the challenges posed by dopaminergic CNS disorders. Her contributions have the potential to improve the quality of life for many individuals affected by these conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile